<DOC>
	<DOCNO>NCT00063388</DOCNO>
	<brief_summary>Determine tumor response rate time disease progression , survival safety total population .</brief_summary>
	<brief_title>Phase II Study Patients With Recurrent Non-Small-Cell Lung Cancer</brief_title>
	<detailed_description>To determine tumor response rate time disease progression , survival safety EGFR-positive , EGFR-negative total population .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Inclusion Criteria 1 . Subjects recurrent progressive NSCLC either present prior histologic confirmation pathologic confirmation NSCLC 2 . Subjects receive 1 prior chemotherapy regimens treatment recurrent/metastatic disease , include least 1 platinumbased combination 3 . Unidimensionally measurable NSCLC 4 . Subjects tumor tissue available EGFR assessment 5 . ECOG performance status 0 1 6 . Subjects asymptomatic brain metastasis eligible ; however , must complete radiotherapy/radiosurgery least 3 week prior enrollment steroid Exclusion Criteria 1 . Women childbearing potential unwilling unable use acceptable method avoid pregnancy entire study period 4 week study . Male subject must also agree use effective contraception 2 . Women childbearing potential use prohibit contraceptive method 3 . Women pregnant breastfeed 4 . Women positive pregnancy test enrollment prior study drug administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Non</keyword>
	<keyword>Small</keyword>
	<keyword>Cell</keyword>
	<keyword>Lung</keyword>
	<keyword>Cancer</keyword>
</DOC>